Company Overview

Medexus is a leading orphan drug and rare disease pharmaceutical company with a strong North American commercial platform and a growing portfolio of innovative treatment solutions. Medexus's current focus is on the therapeutic areas of hematology and hematology-oncology and rheumatology and allergy.

GRAFAPEX, an alkylating drug indicated for use in combination with fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation, represents a significant growth opportunity for Medexus. This is driven by its potential to address unmet needs in transplant medicine and expand the company's presence within hematology-oncology. With increasing adoption across transplant centers, GRAFAPEX could become a key driver of revenue growth and long-term value creation for the company.

Medexus Announces Fiscal Year 2026 Results, Demonstrating Continued Momentum and Strong Product-Level Performance of GRAFAPEX (treosulfan) for Injection
Jun 25 2026, 6:00 PM EDT

Medexus Schedules Fourth Fiscal Quarter and Fiscal Year 2026 Conference Call
Jun 16 2026, 5:30 PM EDT

Medexus Announces License and Supply Deal for UM171 Cell Therapy in Canada
Jun 9 2026, 5:30 PM EDT

Management Team

Ken d'Entremont
Chief Executive Officer and Director

Brendon Buschman
Chief Financial Officer

Ian C Wildgoose Brown
General Counsel

Medexus Pharmaceuticals, Inc.

10 King Street East, Suite 600
Toronto, ON M5C 1C3
Canada

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and it's quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.